{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=2",
    "query": {
      "intervention": "matched placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T03:47:35.803Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07262268",
      "title": "A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Familial Erythromelalgia"
      ],
      "interventions": [
        {
          "name": "BHV-7000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2026-01-15",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07262268"
    },
    {
      "nct_id": "NCT04039113",
      "title": "Tezepelumab COPD Exacerbation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Tezepelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 337,
      "start_date": "2019-07-30",
      "completion_date": "2024-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 27,
      "location_summary": "Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04039113"
    },
    {
      "nct_id": "NCT02579876",
      "title": "Milk Patch for Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Esophagitis",
        "Milk Allergy"
      ],
      "interventions": [
        {
          "name": "Viaskin Milk 500 mcg",
          "type": "DRUG"
        },
        {
          "name": "Viaskin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-10",
      "completion_date": "2018-11-20",
      "has_results": true,
      "last_update_posted_date": "2019-07-10",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579876"
    },
    {
      "nct_id": "NCT00417417",
      "title": "Rilonacept to Improve Artery Function in Patients With Atherosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Atherosclerosis",
        "Inflammation",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "Rilonacept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2006-12",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2012-04-30",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417417"
    },
    {
      "nct_id": "NCT01721317",
      "title": "Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Ezogabine/Retigabine IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2012-12-19",
      "completion_date": "2013-06-20",
      "has_results": true,
      "last_update_posted_date": "2020-12-30",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 9,
      "location_summary": "Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721317"
    },
    {
      "nct_id": "NCT06846710",
      "title": "Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "HS-20118",
          "type": "DRUG"
        },
        {
          "name": "HS-20118 placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jiangsu Hansoh Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 132,
      "start_date": "2025-05-02",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Miami Lakes, Florida • Pompano Beach, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06846710"
    },
    {
      "nct_id": "NCT04467840",
      "title": "Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "Lung Infection"
      ],
      "interventions": [
        {
          "name": "Opaganib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 475,
      "start_date": "2020-08-21",
      "completion_date": "2021-07-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04467840"
    },
    {
      "nct_id": "NCT00404768",
      "title": "The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obstetric Labour, Premature"
      ],
      "interventions": [
        {
          "name": "GSK221149A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 93,
      "start_date": "2007-10-12",
      "completion_date": "2011-07-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 32,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00404768"
    },
    {
      "nct_id": "NCT01487460",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dyslipidemia",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAP311",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 137,
      "start_date": "2011-11",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01487460"
    },
    {
      "nct_id": "NCT02653482",
      "title": "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Heart Failure With Reduced Systolic Function"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint Luke's Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "119 Years",
        "sex": "ALL",
        "summary": "19 Years to 119 Years"
      },
      "enrollment_count": 263,
      "start_date": "2016-03-03",
      "completion_date": "2019-06-28",
      "has_results": true,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-09-02T03:47:35.803Z",
      "location_count": 25,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653482"
    }
  ]
}